First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle(TM) Platform

First two GMP doses of rese-cel manufactured on the Cell Shuttle(TM) met all release specifications, were delivered on time, and have been infused into patients within Cabaletta Bio's RESET(TM) ...
Rutland Herald

Kincell Bio Announces Strategic Expansion of Research Triangle Park Facility to Support Late-Stage and Commercial Cell Therapy Manufacturing Programs

Kincell Bio, a leading contract development and manufacturing organization (CDMO) supporting autologous and allogeneic cell ...
GEN - Genetic Engineering and Biotechnology News

CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients

The dosing of these two patients demonstrates Cellares’ GMP manufacturing and supply chain capabilities with their automated platform.

Hinge Bio Announces First Subject Dosed in Phase 1 Trial of HB2198, a Novel B cell Depleting Agent, for Treating Autoimmune Disease

First-in-human clinical trial underway to evaluate safety, tolerability and pharmacodynamic activity of HB2198 in normal healthy volunteers. A separate Phase 1 trial evaluating HB2198 in patients with ...